Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CAPS Stock Alerts

Capstone Therapeutics (CAPS) Competitors

Capstone Therapeutics logo
$0.38 -0.03 (-6.15%)
Closing price 04:00 PM Eastern
Extended Trading
$0.39 +0.00 (+0.81%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CAPS vs. PASG, CVKD, KTTA, NAII, and GNTA

Should you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include Passage Bio (PASG), Cadrenal Therapeutics (CVKD), Pasithea Therapeutics (KTTA), Natural Alternatives International (NAII), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry.

How does Capstone Therapeutics compare to Passage Bio?

Capstone Therapeutics (NASDAQ:CAPS) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Capstone Therapeutics has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.11-$21.23M-$3.63N/A
Passage BioN/AN/A-$45.52M-$14.48N/A

Passage Bio has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -45.01%. Capstone Therapeutics' return on equity of -93.49% beat Passage Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-45.01% -93.49% -39.69%
Passage Bio N/A -135.04%-60.37%

In the previous week, Passage Bio had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 1 mentions for Passage Bio and 0 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company Overall Sentiment
Capstone Therapeutics Neutral
Passage Bio Neutral

Capstone Therapeutics has a beta of -1.52, indicating that its share price is 252% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 210.30%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Passage Bio
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 59.1% of Capstone Therapeutics shares are owned by insiders. Comparatively, 4.9% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Passage Bio beats Capstone Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Capstone Therapeutics compare to Cadrenal Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Cadrenal Therapeutics has lower revenue, but higher earnings than Capstone Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.11-$21.23M-$3.63N/A
Cadrenal TherapeuticsN/AN/A-$13.24M-$6.68N/A

Cadrenal Therapeutics has a consensus target price of $13.00, indicating a potential upside of 105.70%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Cadrenal Therapeutics had 5 more articles in the media than Capstone Therapeutics. MarketBeat recorded 5 mentions for Cadrenal Therapeutics and 0 mentions for Capstone Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.03 beat Capstone Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Capstone Therapeutics Neutral
Cadrenal Therapeutics Neutral

Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 59.1% of Capstone Therapeutics shares are held by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cadrenal Therapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -45.01%. Capstone Therapeutics' return on equity of -93.49% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-45.01% -93.49% -39.69%
Cadrenal Therapeutics N/A -333.30%-236.95%

Summary

Cadrenal Therapeutics beats Capstone Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Capstone Therapeutics compare to Pasithea Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 59.1% of Capstone Therapeutics shares are held by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 0 mentions for Capstone Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.69 beat Capstone Therapeutics' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Capstone Therapeutics Neutral
Pasithea Therapeutics Positive

Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 252.94%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pasithea Therapeutics
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

Pasithea Therapeutics has lower revenue, but higher earnings than Capstone Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.11-$21.23M-$3.63N/A
Pasithea TherapeuticsN/AN/A-$20.43M-$3.57N/A

Pasithea Therapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -45.01%. Pasithea Therapeutics' return on equity of -85.48% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-45.01% -93.49% -39.69%
Pasithea Therapeutics N/A -85.48%-77.42%

Summary

Pasithea Therapeutics beats Capstone Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Capstone Therapeutics compare to Natural Alternatives International?

Capstone Therapeutics (NASDAQ:CAPS) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Natural Alternatives International had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

Company Overall Sentiment
Capstone Therapeutics Neutral
Natural Alternatives International Neutral

Natural Alternatives International has higher revenue and earnings than Capstone Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.11-$21.23M-$3.63N/A
Natural Alternatives International$129.86M0.12-$13.57M-$2.04N/A

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 59.1% of Capstone Therapeutics shares are held by insiders. Comparatively, 20.8% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Natural Alternatives International has a net margin of -9.06% compared to Capstone Therapeutics' net margin of -45.01%. Natural Alternatives International's return on equity of -8.60% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-45.01% -93.49% -39.69%
Natural Alternatives International -9.06%-8.60%-3.92%

Capstone Therapeutics has a beta of -1.52, indicating that its stock price is 252% less volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Summary

Natural Alternatives International beats Capstone Therapeutics on 10 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to Genenta Science?

Capstone Therapeutics (NASDAQ:CAPS) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 59.1% of Capstone Therapeutics shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genenta Science has lower revenue, but higher earnings than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.11-$21.23M-$3.63N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Genenta Science has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -45.01%. Genenta Science's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-45.01% -93.49% -39.69%
Genenta Science N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

In the previous week, Capstone Therapeutics' average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company Overall Sentiment
Capstone Therapeutics Neutral
Genenta Science Neutral

Summary

Genenta Science beats Capstone Therapeutics on 6 of the 8 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPS vs. The Competition

Export
MetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.89M$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E RatioN/A38.8529.0428.48
Price / Sales0.11157.28477.1060.43
Price / CashN/A57.8827.6236.52
Price / Book0.287.039.676.67
Net Income-$21.23M$23.62M$3.55B$332.64M
7 Day Performance-6.45%3.67%1.70%2.01%
1 Month Performance-33.71%7.17%5.62%9.19%
1 Year Performance-78.49%67.04%34.42%39.59%

Capstone Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CAPS
Capstone Therapeutics
0.7867 of 5 stars		$0.38
-6.2%		N/AN/A$5.89M$48.11MN/A38
PASG
Passage Bio
3.2453 of 5 stars		$5.84
-0.1%		$13.25
+127.0%		N/A$18.91MN/AN/A130
CVKD
Cadrenal Therapeutics
2.4139 of 5 stars		$5.71
+3.7%		$13.00
+127.9%		N/A$17.57MN/AN/A4
KTTA
Pasithea Therapeutics
2.241 of 5 stars		$0.70
+1.9%		$3.00
+326.7%		N/A$17.53MN/AN/A3
NAII
Natural Alternatives International
1.0363 of 5 stars		$2.82
+5.7%		N/AN/A$17.44M$129.86MN/A290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel